Additional effects of irbesartan when compared to captopril in the prevention of post-infarction left ventricular dilatation.
Parkhomenko
Alexander N
AN
Institute of Cardiology, N. D. Strazhesko Ukrainian Academy of Medical Sciences, Kiev.
Irkin
Oleg I
OI
Kushnir
Sergey P
SP
Bryl
Zhanna V
ZV
Soliarik
Oksana
O
Shkliar
Lilia V
LV
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000627:therapeutic use*; D002216:Captopril / Q000627:therapeutic use*; D004108:Dilatation, Pathologic; D006352:Heart Ventricles / Q000473:pathology*; D006801:Humans; D000077405:Irbesartan; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D013777:Tetrazoles / Q000627:therapeutic use*
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D001713:Biphenyl Compounds; D013777:Tetrazoles; D002216:Captopril; D000077405:Irbesartan